Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 13/20 | 0.56 |
| ▸ | S1PR3 | Q99500 | 8/20 | 0.56 |
| ▸ | S1PR4 | O95977 | 6/20 | 0.52 |
| ▸ | TNNC1 | P63316 | 5/20 | 0.52 |
| ▸ | S1PR5 | Q9H228 | 5/20 | 0.52 |
| ▸ | SGPL1 | O95470 | 1/20 | 0.52 |
| ▸ | GPR183 | P32249 | 1/20 | 0.52 |
| ▸ | CERS2 | Q96G23 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.46 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3392638 | 1.00 | S1PR1 (0.56) | S1PR1S1PR3S1PR4TNNC1S1PR5 | |
| SCHEMBL8499757 | 0.87 | S1PR1 (0.54) | S1PR1S1PR3S1PR4TNNC1S1PR5 | |
| SCHEMBL8496582 | 0.87 | S1PR1 (0.54) | S1PR1S1PR3S1PR4TNNC1S1PR5 | |
| SCHEMBL8498934 | 0.87 | S1PR1 (0.54) | S1PR1S1PR3S1PR4TNNC1S1PR5 | |
| SCHEMBL8525809 | 0.86 | S1PR1 (0.57) | S1PR1S1PR3S1PR4TNNC1S1PR5 | |
| SCHEMBL13614226 | 0.86 | S1PR1 (0.57) | S1PR1S1PR3S1PR4TNNC1S1PR5 | |
| SCHEMBL13563466 | 0.86 | S1PR1 (0.57) | S1PR1S1PR3S1PR4TNNC1S1PR5 | |
| SCHEMBL3393720 | 0.86 | S1PR1 (0.73) | S1PR1S1PR3S1PR4TNNC1S1PR5 | |
| SCHEMBL3393258 | 0.86 | S1PR1 (0.73) | S1PR1S1PR3S1PR4TNNC1S1PR5 | |
| SCHEMBL2010273 | 0.86 | S1PR1 (0.73) | S1PR1S1PR3S1PR4TNNC1S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7524887-B2 | 2-amino-1,3-propanediol compounds for the treatment of acute pain | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-04-28 | — | — | US | claimed |
| EP-1635803-B1 | USE OF 2-AMINO-1-3-PROPANEDIOL DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF VARIOUS TYPES OF PAIN | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-03-04 | — | — | EP | claimed |
| EP-1635803-A1 | USE OF 2-AMINO-1-3-PROPANEDIOL DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF VARIOUS TYPES OF PAIN | Sanofi-Aventis Deutschland GmbH (DE) | 2006-03-22 | — | — | EP | claimed |
| WO-2004110421-A1 | USE OF 2-AMINO-1-3-PROPANEDIOL DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF VARIOUS TYPES OF PAIN | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-12-23 | — | — | WO | claimed |
| US-20040248988-A1 | 2-Amino-1,3-propanediol compounds for the treatment of various types of pain | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-12-09 | — | — | US | claimed |
| EP-1484057-A1 | USE OF 2-AMINO-1-3-PROPANEDIOL DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF VARIOUS TYPES OF PAIN | Aventis Pharma Deutschland GmbH (DE) | 2004-12-08 | — | — | EP | claimed |
| EP-0627406-B1 | 2-AMINO-1,3-PROPANEDIOL COMPOUND AND IMMUNOSUPPRESSANT | YOSHITOMI PHARMACEUTICAL (JP) | 1998-10-28 | — | — | EP | claimed |
| EP-0627406-A1 | 2-AMINO-1,3-PROPANEDIOL COMPOUND AND IMMUNOSUPPRESSANT | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1994-12-07 | — | — | EP | claimed |
| US-9763980-B2 | Combined chemical modification of sphingosine-1-phosphate (S1P) and CXCR4 signalling pathways for hematopoietic stem cell (HSC) mobilization and engraftment | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2017-09-19 | — | — | US | disclosed |
| US-20140193376-A1 | COMBINED CHEMICAL MODIFICATION OF SPHINGOSINE-1-PHOSPHATE (S1P) AND CXCR4 SIGNALLING PATHWAYS FOR HEMATOPOIETIC STEM CELL (HSC) MOBILIZATION AND ENGRAFTMENT | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2014-07-10 | — | — | US | disclosed |
| EP-1987066-B1 | METHODS FOR TREATING DEMYELINATING DISEASES | UNIV ZUERICH (CH) | 2010-12-29 | — | — | EP | disclosed |
| US-20090136450-A1 | THERAPY FOR NEUROLOGICAL DISEASES | ARES TRADING S.A. (CH) | 2009-05-28 | — | — | US | disclosed |
| US-7524887-B2 | 2-amino-1,3-propanediol compounds for the treatment of acute pain | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-04-28 | — | — | US | disclosed |
| EP-1635803-B1 | USE OF 2-AMINO-1-3-PROPANEDIOL DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF VARIOUS TYPES OF PAIN | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-03-04 | — | — | EP | disclosed |
| EP-1484057-A1 | USE OF 2-AMINO-1-3-PROPANEDIOL DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF VARIOUS TYPES OF PAIN | Aventis Pharma Deutschland GmbH (DE) | 2004-12-08 | — | — | EP | disclosed |
| US-5952316-A | FOR TREATING AUTOIMMUNE DISEASES, E.G., RHEUMATIOD ARTHRITIS | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1999-09-14 | — | — | US | disclosed |
| EP-0627406-B1 | 2-AMINO-1,3-PROPANEDIOL COMPOUND AND IMMUNOSUPPRESSANT | YOSHITOMI PHARMACEUTICAL (JP) | 1998-10-28 | — | — | EP | disclosed |
| US-5719176-A | 2-amino-1,3-propanediol compound and immunosuppressant | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1998-02-17 | — | — | US | disclosed |
| US-5604229-A | 2-amino-1,3-propanediol compound and immunosuppressant | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1997-02-18 | — | — | US | disclosed |
| EP-0627406-A1 | 2-AMINO-1,3-PROPANEDIOL COMPOUND AND IMMUNOSUPPRESSANT | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1994-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248988-A1 | 2-Amino-1,3-propanediol compounds for the treatment of various types of pain | PTGER1, PTGER2, PTGER3 | S1PR1 1462/4885S1PR3 884/4885S1PR4 2615/4885 |
| US-20140193376-A1 | COMBINED CHEMICAL MODIFICATION OF SPHINGOSINE-1-PHOSPHATE (S1P) AND CXCR4 SIGNALLING PATHWAYS FOR HEMATOPOIETIC STEM CELL (HSC) MOBILIZATION AND ENGRAFTMENT | S1PR1, S1PR4, S1PR3 | S1PR1 1/4885S1PR3 3/4885S1PR4 2/4885 |
| US-20090136450-A1 | THERAPY FOR NEUROLOGICAL DISEASES | KIT, NGF, PMP22 | S1PR1 377/4885S1PR3 479/4885S1PR4 671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.